{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:51:43Z","timestamp":1761094303759,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.bbmt.2016.01.015","type":"journal-article","created":{"date-parts":[[2016,1,16]],"date-time":"2016-01-16T12:01:07Z","timestamp":1452945667000},"page":"941-948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis"],"prefix":"10.1016","volume":"22","author":[{"given":"Danielle H.","family":"Oh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haocheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuli","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Villa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthea","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Chua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn J.","family":"Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M.","family":"Connors","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas A.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2016.01.015_bib1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","article-title":"Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project","volume":"9","author":"Anderson","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2016.01.015_bib2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"issue":"Suppl 3","key":"10.1016\/j.bbmt.2016.01.015_bib3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/annonc\/mdu200","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Dreyling","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2016.01.015_bib4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ajh.23674","article-title":"Follicular lymphoma: 2014 update on diagnosis and management","volume":"89","author":"Freedman","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2016.01.015_bib5","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.01.015_bib6","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.01.015_bib7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2016.01.015_bib8","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1038\/sj.leu.2404850","article-title":"Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study","volume":"21","author":"Montoto","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2016.01.015_bib9","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.3109\/10428194.2011.594925","article-title":"Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score","volume":"52","author":"Peters","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2016.01.015_bib10","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/annonc\/mds657","article-title":"Long-term clinical and molecular remissions in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation","volume":"24","author":"Metzner","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2016.01.015_bib11","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3324\/haematol.2012.069583","article-title":"Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse","volume":"98","author":"Montoto","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2016.01.015_bib12","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/bmt.2013.83","article-title":"The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT","volume":"48","author":"Robinson","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.01.015_bib13","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3324\/haematol.2010.030320","article-title":"Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA\/GOELAMS FL2000 study","volume":"96","author":"Le Gouill","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2016.01.015_bib14","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","article-title":"Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up","volume":"25","author":"Rohatiner","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.01.015_bib15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.23872","article-title":"The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi","volume":"90","author":"Rossi","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2016.01.015_bib16","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1002\/cncr.28243","article-title":"Stem cell transplantation for follicular lymphoma relapsed\/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project","volume":"119","author":"Evens","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2016.01.015_bib17","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.01.015_bib18","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1200\/JCO.2012.41.6701","article-title":"Comparative effectiveness research in oncology methodology: observational data","volume":"30","author":"Hershman","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.01.015_bib19","doi-asserted-by":"crossref","first-page":"c2073","DOI":"10.1136\/bmj.c2073","article-title":"An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials","volume":"340","author":"Sussman","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.bbmt.2016.01.015_bib20","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/sim.6128","article-title":"Instrumental variable methods for causal inference","volume":"33","author":"Baiocchi","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.bbmt.2016.01.015_bib21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1513\/AnnalsATS.201303-054FR","article-title":"Instrumental variable analyses. Exploiting natural randomness to understand causal mechanisms","volume":"10","author":"Iwashyna","year":"2013","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.bbmt.2016.01.015_bib22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhealeco.2007.09.009","article-title":"Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling","volume":"27","author":"Terza","year":"2008","journal-title":"J\u00a0Health Econ"},{"key":"10.1016\/j.bbmt.2016.01.015_bib23","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/j.1475-6773.2007.00807.x","article-title":"The use of linear instrumental variables methods in health services research and health economics: a cautionary note","volume":"43","author":"Terza","year":"2008","journal-title":"Health Serv Res"},{"issue":"Suppl 3","key":"10.1016\/j.bbmt.2016.01.015_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428194.2011.629897","article-title":"Clinical practice guidelines for first-line\/after-relapse treatment of patients with follicular lymphoma","volume":"52","author":"Lopez-Guillermo","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2016.01.015_bib25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ajh.23372","article-title":"SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma","volume":"88","author":"Zinzani","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2016.01.015_bib26","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3324\/haematol.2013.084723","article-title":"Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party","volume":"98","author":"Montoto","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2016.01.015_bib27","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/bjh.12741","article-title":"Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure","volume":"165","author":"Kothari","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2016.01.015_bib28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/jnci\/djr450","article-title":"Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis","volume":"104","author":"Al Khabori","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.bbmt.2016.01.015_bib29","unstructured":"Canadian Cancer Statistics 2014. Retrieved from http:\/\/www.cancer.ca."},{"key":"10.1016\/j.bbmt.2016.01.015_bib30","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.01.015_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2014-04-516815","article-title":"Transformed follicular non-Hodgkin lymphoma","volume":"125","author":"Casulo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.01.015_bib32","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.2012.44.0693","article-title":"Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian Blood and Marrow Transplant group","volume":"31","author":"Villa","year":"2013","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116000550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116000550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:56:20Z","timestamp":1761058580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879116000550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S1083879116000550"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.01.015","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}